NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Sample GSM724282 Query DataSets for GSM724282
Status Public on Aug 19, 2012
Title underPatient6-1
Sample type RNA
 
Channel 1
Source name non tumor lesion of liver biopsy, 8weeks after starting peretinoin administration
Organism Homo sapiens
Characteristics patient: 6-1
tissue: non tumor lesion of liver biopsy
agent: peretinoin
time: 8 weeks
agent dose: 300mg
clincal outcome: Recurrence of HCC
Treatment protocol Peretinoin, a member of the acyclic retinoid family, is expected to be an effective chemo preventive drug for HCC.The patients had undergone curative surgical resection or radiofrequency ablation (RFA). They received 300 mg/day or 600 mg/day of peretinoin for 8 weeks and were followed up for 88 weeks with 600 mg/day of peretinoin. Hepatic gene expression profiling obtained from non tumor lesion of these patients prior to administering peretinoin and 8 weeks after starting peretinoin treatment
Extracted molecule total RNA
Extraction protocol Total RNA was isolated from liver biopsy samples using an RNA extraction kit (Micro RNA Extraction Kit, Stratagene, La Jolla, CA, USA). Aliquots of total RNA (5 ug) were subjected to amplification with antisense RNA (aRNA) using a Message AmpTM aRNA kit (Ambion, Austin, TX, USA) as recommended by the manufacturer
Label Cy5
Label protocol As a reference for each microarray analysis, aRNA samples prepared from the normal liver tissue from one of the patients were used. Test RNA samples fluorescently labeled with cyanine (Cy) 5 and reference RNA labeled with Cy3 were used for microarray hybridization
 
Channel 2
Source name normal liver sample from a patient [reference]
Organism Homo sapiens
Characteristics tissue: normal liver
Treatment protocol Peretinoin, a member of the acyclic retinoid family, is expected to be an effective chemo preventive drug for HCC.The patients had undergone curative surgical resection or radiofrequency ablation (RFA). They received 300 mg/day or 600 mg/day of peretinoin for 8 weeks and were followed up for 88 weeks with 600 mg/day of peretinoin. Hepatic gene expression profiling obtained from non tumor lesion of these patients prior to administering peretinoin and 8 weeks after starting peretinoin treatment
Extracted molecule total RNA
Extraction protocol Total RNA was isolated from liver biopsy samples using an RNA extraction kit (Micro RNA Extraction Kit, Stratagene, La Jolla, CA, USA). Aliquots of total RNA (5 ug) were subjected to amplification with antisense RNA (aRNA) using a Message AmpTM aRNA kit (Ambion, Austin, TX, USA) as recommended by the manufacturer
Label Cy3
Label protocol As a reference for each microarray analysis, aRNA samples prepared from the normal liver tissue from one of the patients were used. Test RNA samples fluorescently labeled with cyanine (Cy) 5 and reference RNA labeled with Cy3 were used for microarray hybridization
 
 
Hybridization protocol Reference papers; Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Kaneko S. Hepatology. 2006 Nov;44(5):1122-38, Honda M, Kaneko S, Kawai H, Shirota Y, Kobayashi K. Gastroenterology. 2001 Mar;120(4):955-66.
Scan protocol Quantitative assessment of the signals on the slides was carried out by scanning on a ScanArray 5000 (General Scanning, Watertown, MA, USA) followed by image analysis using GenePix Pro 4.1(Axon Instruments, Union City, CA, USA)
Description 300mgRecurrence
Data processing Because the levels of expression of some housekeeping genes were also changed, especially in advanced stages of liver disease, for the normalization of data we averaged intensities of all spots obtained with Cy3 and Cy5 in each of the 16 rectangles and adjusted intensity of each corrected DNA spot as the average intensity ratio Cy5/Cy3 = 1.0. This global normalization of intensity provided smaller variance of CyS/Cy3 ratio and almost equivalent results to normalization using the housekeeping genes.
Reference papers; Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Kaneko S. Hepatology. 2006 Nov;44(5):1122-38, Honda M, Kaneko S, Kawai H, Shirota Y, Kobayashi K. Gastroenterology. 2001 Mar;120(4):955-66.
 
Submission date May 15, 2011
Last update date Aug 19, 2012
Contact name Masao Honda
E-mail(s) mhondag@gmail.com
Phone 0762652243
Organization name Kanazawa University
Department Gastroenterology
Street address Takara-Machi 13-1
City Kanazawa
ZIP/Postal code 920-8641
Country Japan
 
Platform ID GPL13536
Series (1)
GSE29302 Acyclic retinoid targets platelet-derived growth factor signaling in the prevention of hepatic fibrosis and hepatocellular carcinoma development

Data table header descriptions
ID_REF
VALUE log2 of PRE_VALUE; normalized log2 ratio (Cy5/Cy3) representing test/reference
PRE_VALUE normalized ratio (Cy5/Cy3) representing test/reference

Data table
ID_REF VALUE PRE_VALUE
1001 -0.1758 0.885277579
1002 -0.0841 0.943394998
1003 -0.6579 0.633817167
1004 0.4156 1.333824148
1005 -0.0648 0.956072572
1006 0.3174 1.246090158
1007 0.6669 1.587660678
1008 0.2309 1.173546182
1009 0.2413 1.182092977
1010 0.3550 1.278957765
1011 -0.2526 0.839384517
1012 0.6463 1.565153955
1013 1.7790 3.431976629
1014 0.3259 1.2534826
1015 0.5630 1.477385937
1016 0.0054 1.003780435
1017 0.5843 1.49928203
1018 0.4293 1.346608932
1019 0.4896 1.404057645
1020 0.8484 1.800471892

Total number of rows: 9643

Table truncated, full table size 227 Kbytes.




Supplementary file Size Download File type/resource
GSM724282_084hn1.gpr.gz 923.1 Kb (ftp)(http) GPR
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap